Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses (Q36584432)

15 August 2017

1 reference

title

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses (English)

1 reference

15 August 2017

0 references

Peter Sasieni

0 references

Joakim Dillner

1 reference

15 August 2017

Marc Arbyn

1 reference

15 August 2017

George Koliopoulos

1 reference

15 August 2017

Chris J L M Meijer

1 reference

15 August 2017

Christine Clavel

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24 Suppl 3

1 reference

15 August 2017

page(s)

S3/78-89

1 reference

The causal relation between human papillomavirus and cervical cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Re: Have We Resolved How To Triage Equivocal Cervical Cytology?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

The carcinogenicity of human papillomavirus types reflects viral evolution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.117

10.1016/J.VACCINE.2006.05.117

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference